有投资者问中研股份，据公开信息，2023年12月，公司与康拓医疗合作的使用中研股份医疗级PEEK（材料牌号：ZR3G）的创新医疗器械已获得国家药品监督管理局注册，公司万级洁净GMP车间已投入使用。植入级医疗PEEK产品也在2024年4月CHINAPLAS国际橡塑展上首秀。请问公司目前医疗PEEK产品相关的订单情况？产品未来的市场前景如何？中研股份在互动平台表示，公司医疗级PEEK目前有小批量订单交付，部分项目仍处在开发验证阶段。公司持续看好PEEK产品在医疗植入领域的应用。
English
Back
- Markets
- Features
- News
- Community
- Learn
- Help Center
- About
- Offers & Rewards
- Welcome BonusOpen an account and get up to HKD1600!
- Enjoy limited-time 5%+5% returns on Cash PlusInvest any amount and enjoy a 5% average return on Cash Plus + 5% welcome reward
- Learn PremiumAnalyst 1V1 online teaching
- Referral PromotionBring a friend and collect up to HK$600 in rewards
- Stock TransferSwitch to Futu and get up to HK$7,000 in rewards
- English
- 繁體中文
- 简体中文
- Dark
- Light
中研股份：医疗级PEEK目前有小批量订单交付 部分项目仍处在开发验证阶段
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.
Write a comment
0 0 0
LikeLoveLaughing CryRespectEmmSadAngry
Tap to Select a Mood
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
Use the share button in your browser
to share the page with your friends
Tap here to share
No comments yet. Write one.